Condition: Multiple Sclerosis · Sponsor: Bristol-Myers Squibb
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
This description comes directly from the study's public registry record.
BMS Study Connect Contact Center www.BMSStudyConnect.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site #.
Always discuss trial participation with your own doctor first.
| Evidera INC. | Bethesda, Maryland, United States | Recruiting |
| Evidera | Bethesda, Maryland, United States | Recruiting |
| Marienhospital Herne, Klinikum Der Ruhr-Universitaet Bochum | Herne, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05170126